Improved antiangiogenic and antitumour activity of the combination of the natural flavonoid fisetin and cyclophosphamide in Lewis lung carcinoma-bearing mice
- 11 November 2010
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cancer Chemotherapy and Pharmacology
- Vol. 68 (2), 445-455
- https://doi.org/10.1007/s00280-010-1505-8
Abstract
The natural flavonoid fisetin was recently identified as a lead compound that stabilizes endothelial cell microtubules. In this study, we investigated the antiproliferative and antiangiogenic properties of fisetin in vitro and in vivo. Fisetin cytotoxicity was evaluated using Lewis lung carcinoma cells (LLC), endothelial cells and NIH 3T3 cells. Endothelial cell (EC) migration and capillary-like structure formation were evaluated using EAhy 926 cells. In vivo tumour growth inhibition studies were performed using LLC-bearing mice treated with fisetin and/or cyclophosphamide (CPA). The fisetin IC50 was 59 μM for LLC and 77 μM for EC cells, compared to 210 μM for normal NIH 3T3 cells (24 h). Fisetin inhibited EC migration and capillary-like structure formation at non-cytotoxic concentrations (22–44 μM). In mice, fisetin inhibited angiogenesis assessed using the Matrigel plug assay. In LLC-bearing mice, fisetin produced a 67% tumour growth inhibition (223 mg/kg, intraperitoneal), similar to the 66% produced by low-dose CPA (30 mg/kg, subcutaneous). When fisetin and CPA were combined, however, a marked improvement in antitumour activity was observed (92% tumour growth inhibition), with low systemic toxicity. Tumour histology showed decreased microvessel density with either fisetin or CPA alone, and a dramatic decrease after the fisetin/CPA combination. We have shown that fisetin not only displays in vitro and in vivo antiangiogenic properties, but also can markedly improve the in vivo antitumour effect of CPA. We propose that this drug combination associating a non-toxic dietary flavonoid with a cytotoxic agent could advantageously be used in the treatment of solid tumours.Keywords
This publication has 47 references indexed in Scilit:
- Dietary flavonoid fisetin induces a forced exit from mitosis by targeting the mitotic spindle checkpointCarcinogenesis: Integrative Cancer Research, 2009
- Flavonoid-Induced Morphological Modifications of Endothelial Cells Through Microtubule StabilizationNutrition and Cancer, 2009
- A Novel Dietary Flavonoid Fisetin Inhibits Androgen Receptor Signaling and Tumor Growth in Athymic Nude MiceCancer Research, 2008
- Flavonoids Affect Actin Functions in Cytoplasm and NucleusBiophysical Journal, 2007
- Fisetin, an Inhibitor of Cyclin-Dependent Kinase 6, Down-Regulates Nuclear Factor-κB-Regulated Cell Proliferation, Antiapoptotic and Metastatic Gene Products through the Suppression of TAK-1 and Receptor-Interacting Protein-Regulated IκBα Kinase ActivationMolecular Pharmacology, 2007
- Angiogenesis in life, disease and medicineNature, 2005
- Crystal Structure of a Human Cyclin-Dependent Kinase 6 Complex with a Flavonol Inhibitor, FisetinJournal of Medicinal Chemistry, 2005
- Cancer chemoprevention with dietary phytochemicalsNature Reviews Cancer, 2003
- Flavonoids as DNA Topoisomerase Antagonists and Poisons: Structure-Activity RelationshipsJournal of Natural Products, 1995
- Vascular collapse after flavone acetic acid: A possible mechanism of its anti-tumour actionEuropean Journal of Cancer and Clinical Oncology, 1989